Innovotech: Top 10 Undervalued Biotechnology Industry Sector Stocks on TSX Venture Exchange (IOT)
Innovotech is now ranked among the top 10 undervalued stocks in the Biotechnology industry on the TSX Venture Exchange. A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company. Valuation methodology provided by Stockcalc (see below).
All data provided as-at market close September 01, 2022. The list is sorted by stocks with the greatest percentage difference between valuation and price. Innovotech Innovotech Inc offers solutions to client biofilm problems by its biofilm contract research department. Its activities include sales of the products, conducting contract research and research and development to identify products for commercialization. Innovotech is listed under IOT on the TSX Venture Exchange.
| Symbol | Name | Close Price | Shares Outstanding | P/E | P/B | Cash per Share | Net Cash per Share |
|---|---|---|---|---|---|---|---|
| IOT-X | Innovotech | 0 | 0 | 0 | 0 | 0 | 0 |
| SVS-X | Solarvest BioEnergy | 0 | 0 | 0 | 0 | 0 | 0 |
| WAVE-X | Waverley Pharma | 0 | 0 | 0 | 0 | 0 | 0 |
| APC-X | Advanced Proteome | 0 | 0 | 0 | 0 | 0 | 0 |
| KNE-X | Kane Biotech | 0 | 0 | 0 | 0 | 0 | 0 |
| PAS-X | Pascal Biosciences | 0 | 0 | 0 | 0 | 0 | 0 |
| ACST-X | Acasti Pharma | 0 | 0 | 0 | 0 | 0 | 0 |
| MSCL-X | Satellos Bioscience | 0 | 0 | 0 | 0 | 0 | 0 |
| XRTX-X | XORTX Therapeutics | 0 | 0 | 0 | 0 | 0 | 0 |
| RP-X | RepliCel Life Sciences | 0 | 0 | 0 | 0 | 0 | 0 |
More about Innovotech
Biotechnology: Biotech and biopharmaceutical companies engaged in research, discovery, development, and production of innovative drug and drugrelated technologies.. Stocks in this category are held primarily for capital appreciation.
Artificial intelligence at Report on Business
Artificial Intelligence at Report on Business Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.
